VentriPoint Diagnostics Ltd (VPTDF)

[teq0904]

53M shares plus 17M out of the money warrants make this a sweet deal for those investors who have located this company. There is no way this company will be below $3/share if Anderson or any other hospitals start buying the product in decent quantities.

The biggest mistake novice biotech investors make is falling in love with a novel product that will be hard to sell and/or is going to be difficult for the FDA to approve it, so it burns huge money for years while the company fights with the hospital buyers after a prolonged fight with the ivory tower theorists at the FDA.
VMS is not novel at all and selling will be relatively easy because it is somewhat of a plug and play addition to hospitals existing ultrasound.

https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00022463